Captrust Financial Advisors Grows Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Captrust Financial Advisors increased its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 22.7% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,825 shares of the company’s stock after purchasing an additional 1,078 shares during the period. Captrust Financial Advisors’ holdings in IDEXX Laboratories were worth $2,408,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Hurley Capital LLC purchased a new position in shares of IDEXX Laboratories during the fourth quarter valued at approximately $29,000. Rialto Wealth Management LLC purchased a new position in shares of IDEXX Laboratories during the fourth quarter valued at approximately $30,000. Retirement Wealth Solutions LLC purchased a new position in shares of IDEXX Laboratories during the fourth quarter valued at approximately $31,000. Kestra Investment Management LLC purchased a new position in shares of IDEXX Laboratories during the fourth quarter valued at approximately $38,000. Finally, Itau Unibanco Holding S.A. raised its holdings in shares of IDEXX Laboratories by 540.0% during the fourth quarter. Itau Unibanco Holding S.A. now owns 96 shares of the company’s stock valued at $40,000 after purchasing an additional 81 shares during the last quarter. 87.84% of the stock is owned by hedge funds and other institutional investors.

IDEXX Laboratories Stock Performance

IDXX opened at $491.70 on Monday. The firm has a market cap of $39.54 billion, a P/E ratio of 46.08, a PEG ratio of 3.41 and a beta of 1.52. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $548.88. The company has a 50 day simple moving average of $423.31 and a two-hundred day simple moving average of $429.00. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Thursday, May 1st. The company reported $2.96 earnings per share for the quarter, topping analysts’ consensus estimates of $2.93 by $0.03. The business had revenue of $998.43 million during the quarter, compared to analyst estimates of $998.25 million. IDEXX Laboratories had a net margin of 22.78% and a return on equity of 55.82%. The company’s revenue was up 3.6% on a year-over-year basis. During the same period in the prior year, the business posted $2.71 earnings per share. Equities analysts forecast that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

IDXX has been the subject of several research reports. StockNews.com raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Friday. Bank of America upped their target price on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a report on Tuesday, February 4th. Barclays upped their target price on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a report on Tuesday, February 4th. Piper Sandler upped their target price on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a report on Monday, February 10th. Finally, Stifel Nicolaus reduced their target price on shares of IDEXX Laboratories from $450.00 to $420.00 and set a “hold” rating for the company in a report on Monday, April 14th. Three analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $524.75.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.